Extension Study to Evaluate Safety and Efficacy of Jaktinib in Adults With Alopecia Areata

Last updated: March 13, 2025
Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Overall Status: Completed

Phase

3

Condition

Hair Loss

Alopecia

Treatment

Jaktinib

Clinical Study ID

NCT05255237
ZGJAK020
  • Ages 18-65
  • All Genders

Study Summary

This study (Unique Protocol ID: ZGJAK020) as an extension of the ongoing "Study to Evaluate Safety and Efficacy of Jaktinib in Adults With Alopecia Areata (Unique Protocol ID:ZGJAK020)" study. After completion of ZGJAK018 study, the study will be directly extend with an "open-label design".

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Subjects voluntarily sign the informed consent form.

  • Patients who participated in ZGJAK018.

Exclusion

Exclusion Criteria:

  • Subjects who are unsuitable to the trial, as identified by the investigator.

Study Design

Total Participants: 315
Treatment Group(s): 1
Primary Treatment: Jaktinib
Phase: 3
Study Start date:
March 25, 2022
Estimated Completion Date:
June 28, 2024

Connect with a study center

  • 11 Xizhimen South Street

    Beijing, Beijing
    China

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.